GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) last reported results for the quarter ended Jun 2026, with sales of ₹938 crore and net profit of ₹237 crore. The stock last traded at ₹2,540, a market capitalisation of ₹43,030 crore, on a P/E of 40.9. Over the past 52 weeks the stock has ranged between ₹2,088 and ₹3,121. Figures are as of 9 Oct 2026 and are not real time.
GlaxoSmithKline Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹2,540
- Market cap
- ₹43,030 cr
- Stock P/E
- 40.9
- Book value
- ₹134
- ROE
- 45.6%
- ROCE
- 61.4%
- Dividend yield
- 2.24%
- 52w high / low
- 3121/2088
Metrics as of 9 Oct 2026. Not real time.
Track GlaxoSmithKline Pharmaceuticals Ltd
Cruxal reads every GlaxoSmithKline Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
GlaxoSmithKline Pharmaceuticals Ltd growth and returns
- 10 Years
- 3%
- 5 Years
- 5%
- 3 Years
- 6%
- TTM
- 6%
- 10 Years
- 10%
- 5 Years
- 15%
- 3 Years
- 18%
- TTM
- 11%
- 10 Years
- 6%
- 5 Years
- 11%
- 3 Years
- 18%
- 1 Year
- -8%
- 10 Years
- 33%
- 5 Years
- 48%
- 3 Years
- 43%
- Last Year
- 46%
GlaxoSmithKline Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹938 cr, up 16.5% from ₹805 cr a year earlier. Net profit was ₹237 cr, up 15.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 |
| Expenses | 689 | 658 | 641 | 554 | 644 | 670 | 644 | 643 |
| Operating profit | 322 | 292 | 333 | 251 | 336 | 371 | 351 | 296 |
| OPM % | 32% | 31% | 34% | 31% | 34% | 36% | 35% | 31% |
| Other income | 39 | 35 | 41 | 44 | 36 | 50 | 36 | 44 |
| Interest | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 |
| Profit before tax | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 |
| Tax % | 27% | 25% | 27% | 27% | 27% | 26% | 26% | 26% |
| Net profit | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 |
| EPS (₹) | 14.91 | 13.57 | 15.52 | 12.10 | 15.20 | 17.45 | 16.40 | 14.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
GlaxoSmithKline Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 | 3,955 |
| Operating profit | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 909 | 1,179 | 1,309 | 1,354 |
| OPM % | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 26% | 31% | 34% | 34% |
| Net profit | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 1,036 | 1,068 |
| EPS (₹) | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 54.75 | 61.15 | 63.05 |
TTM is the trailing twelve months to the most recent quarter.
GlaxoSmithKline Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 | 2,098 |
| Borrowings | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 19 | 10 | 33 |
| Other liabilities | 995 | 1,889 | 1,771 | 1,315 | 1,602 | 1,950 | 1,570 | 1,760 | 2,147 | 2,023 |
| Total liabilities | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 |
| Fixed assets | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 | 281 |
| CWIP | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 14 | 14 | 33 |
| Investments | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 | 1,392 |
| Other assets | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 | 2,618 |
| Total assets | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 |
As reported by the company. Total assets equal total liabilities by construction.
GlaxoSmithKline Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 234 | 473 | 409 | 490 | 578 | 811 | 484 | 582 | 1,290 | 903 |
| Cash from investing | 301 | -104 | -153 | -57 | 418 | -406 | 808 | 9 | -46 | 397 |
| Cash from financing | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | -562 | -769 | -737 |
| Net cash flow | 24 | 62 | -102 | 6 | 300 | -119 | -251 | 29 | 475 | 563 |
| Free cash flow | -24 | 639 | 166 | 336 | 536 | 2,371 | 451 | 573 | 1,273 | 870 |
| CFO / operating profit | 94% | 133% | 101% | 103% | 121% | 122% | 93% | 92% | 116% | 93% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
GlaxoSmithKline Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 22% | 26% | 31% | 33% | 38% | 37% | 36% | 51% | 63% | 61% |
| Debtor days | 21 | 19 | 14 | 11 | 27 | 23 | 22 | 23 | 28 | 26 |
| Inventory days | 111 | 147 | 131 | 135 | 159 | 144 | 131 | 144 | 126 | 124 |
| Days payable | 73 | 149 | 109 | 100 | 135 | 156 | 122 | 171 | 186 | 154 |
| Cash conversion cycle | 60 | 17 | 36 | 46 | 50 | 11 | 31 | -4 | -31 | -4 |
| Working capital days | 7 | -90 | -72 | -38 | -39 | -94 | -57 | -64 | -99 | -91 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
GlaxoSmithKline Pharmaceuticals Ltd shareholding pattern
Promoters held 75.00% at Jun 2026, broadly unchanged since Jun 2025. FIIs 4.79% and DIIs 7.81%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FIIs | 4.36% | 4.50% | 4.52% | 4.89% | 4.79% | 4.63% | 4.62% | 4.79% |
| DIIs | 7.34% | 7.30% | 7.79% | 7.71% | 7.75% | 7.70% | 7.68% | 7.81% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 13.30% | 13.21% | 12.69% | 12.41% | 12.45% | 12.67% | 12.69% | 12.42% |
| No. of shareholders | 1,19,228 | 1,19,625 | 1,21,885 | 1,23,629 | 1,22,904 | 1,22,460 | 1,21,763 | 1,26,087 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
GlaxoSmithKline Pharmaceuticals Ltd corporate filings
- Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: As per attachment
Read the full analysis - GlaxoSmithKline Pharmaceuticals Limited Announces Successful Shareholder Approval for Board AppointmentsAGM/EGMlow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Limited has successfully concluded its postal ballot…
Read the full analysis - GlaxoSmithKline Pharmaceuticals Ltd: Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd has fulfilled the regulatory requirement under…
Read the full analysis - GlaxoSmithKline Pharmaceuticals Limited issues corrigendum to postal ballot notice regarding executive compensationAGM/EGMlow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Limited has issued a corrigendum to its postal ballot…
Read the full analysis - GlaxoSmithKline Pharmaceuticals Ltd responds to exchange query regarding volume movementCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd has issued a clarification in response to a query…
Read the full analysis - GlaxoSmithKline Pharmaceuticals Ltd: Routine Regulatory Disclosure Under Regulation 30Company Updatelow impact
Cruxal's analysis: The company has filed a routine disclosure under Regulation 30 of the SEBI (Listing…
Read the full analysis - GlaxoSmithKline Pharmaceuticals Ltd: Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: The company has published its financial results in newspapers as per Regulation 30 of the…
Read the full analysis - GlaxoSmithKline Pharmaceuticals announces Postal Ballot for appointment of Non-Executive Director and re-appointment of Managing DirectorAGM/EGMlow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Limited has issued a Postal Ballot notice seeking…
Read the full analysis - GSK Pharmaceuticals files transcript of analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd has filed the transcript of its recent…
Read the full analysis - GlaxoSmithKline Pharmaceuticals receives income tax refund of Rs 52 croresCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd has disclosed the receipt of an income tax refund…
Read the full analysis - GSK Pharmaceuticals announces outcome of analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd has filed the outcome of its analyst/investor meeting…
Read the full analysis - GlaxoSmithKline Pharmaceuticals reports routine newspaper publication under Regulation 30 of LODRCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd. has made a routine announcement regarding a…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.